Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference
April 26 2017 - 4:01PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will webcast its
corporate presentation at the Deutsche Bank 42nd Annual Health Care
Conference on Thursday, May 4th at 12:30 PM ET.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
The presentation will be webcast live and may be accessed from
the Event Calendar page of Sucampo's website at
http://www.sucampo.com/investors/events-presentations/. A replay of
the webcast will also be available on the Company's website for
several days after the live event. To ensure a timely connection,
it is recommended that users register at least 15 minutes prior to
the scheduled webcast.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and
commercialization of specialized medicines that meet major unmet
medical needs of patients worldwide. Sucampo has two marketed
products – AMITIZA, its lead product, and RESCULA – and a
late-stage pipeline of product candidates in clinical development
for orphan disease areas. VTS-270 is a mixture of
2-hydroxypropyl-B-cyclodextrins with a specific compositional
fingerprint that has been granted orphan designation in the U.S.
and Europe and is in a pivotal Phase 2/3 clinical trial for the
treatment of Niemann-Pick Disease Type C-1. Sucampo has an
option for the North American rights to CPP1-x/sulindac, which is
in Phase 3 development for the treatment of familial adenomatous
polyposis and has been granted orphan drug designation in the
U.S. A global company, Sucampo is headquartered in Rockville,
Maryland, and has operations in Japan and Switzerland. For more
information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).Twitter LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2023 to Sep 2024